Chemomab Therapeutics (CMMB) Insider Trading & Ownership $0.98 +0.01 (+1.03%) Closing price 08/6/2025 03:55 PM EasternExtended Trading$0.97 -0.01 (-0.61%) As of 08/6/2025 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Chemomab Therapeutics (NASDAQ:CMMB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.91%Number OfInsiders Buying(Last 3 Years)0Number OfInsiders Selling(Last 3 Years)3Amount OfInsider Selling(Last 3 Years)$1.89M Get CMMB Insider Trade Alerts Want to know when executives and insiders are buying or selling Chemomab Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CMMB Insider Buying and Selling by Quarter Chemomab Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/3/2023Israel Gp Ltd. OrbimedMajor ShareholderSell336,900$3.58$1,206,102.00 11/16/2022George Adi MorInsiderSell324,775$2.08$675,532.00 11/16/2022Neil Harris CohenDirectorSell2,409$2.00$4,818.00 (Data available from 1/1/2013 forward) CMMB Insider Trading Activity - Frequently Asked Questions Who is on Chemomab Therapeutics' Insider Roster? The list of insiders at Chemomab Therapeutics includes George Adi Mor, Israel Gp Ltd. Orbimed, and Neil Harris Cohen. Learn more on insiders at CMMB. What percentage of Chemomab Therapeutics stock is owned by insiders? 11.91% of Chemomab Therapeutics stock is owned by insiders. Learn more on CMMB's insider holdings. Chemomab Therapeutics Key ExecutivesDr. Adi Mor George Ph.D. (Age 42)Co-Founder, Chief Scientific Officer, CEO & Executive Director Compensation: $330kMs. Sigal Fattal CPA (Age 53)M.B.A., Chief Financial Officer Compensation: $322kDr. Matthew B. Frankel M.B.A. (Age 55)M.D., Chief Medical Officer & VP of Drug Development Compensation: $850kBarbara LindheimConsulting Vice President of Investor & Public Relations, Strategic Communications More Insider Trading Tools from MarketBeat Related Companies CABA Insider Trading MIST Insider Trading QNCX Insider Trading ELUT Insider Trading SRZN Insider Trading CELU Insider Trading IMMX Insider Trading CNTX Insider Trading IGMS Insider Trading VNRX Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:CMMB) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMMB Stock Alerts